Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Depreciation and Depletion: 2016-2017

  • UroGen Pharma's Depreciation and Depletion fell 28.40% to $58,000 in Q4 2017 from the same period last year, while for Dec 2017 it was $213,000, marking a year-over-year change of. This contributed to the annual value of $207,000 for FY2017, which is 2.82% down from last year.
  • UroGen Pharma's Depreciation and Depletion amounted to $58,000 in Q4 2017, which was up 241.18% from $17,000 recorded in Q3 2017.
  • In the past 5 years, UroGen Pharma's Depreciation and Depletion ranged from a high of $81,000 in Q4 2016 and a low of $17,000 during Q3 2017.
  • In the last 2 years, UroGen Pharma's Depreciation and Depletion had a median value of $57,500 in 2016 and averaged $53,250.
  • Data for UroGen Pharma's Depreciation and Depletion shows a maximum YoY slumped of 70.18% (in 2017) over the last 5 years.
  • Over the past 2 years, UroGen Pharma's Depreciation and Depletion (Quarterly) stood at $81,000 in 2016, then fell by 28.40% to $58,000 in 2017.
  • Its Depreciation and Depletion was $58,000 in Q4 2017, compared to $17,000 in Q3 2017 and $81,000 in Q4 2016.